Johnson & Johnson (JNJ) has seen various significant events affecting its stock price and overall market. Barclays raised its price target for JNJ following updated estimates. The company's MedTech division plans to shift to a business unit-led structure in 2026. Notably, JNJ's stock increased 40.6% until 2025. However, Mirabella Financial Services LLP, GeoWealth Management LLC, and others reduced their stock position in JNJ. Despite some stock drops, several theories suggest a bullish case for JNJ. The company also announced a collaboration with the
New York Jets for health promotion in the community.
Johnson & Johnson's third-quarter earnings and clear strides in medicines and therapies contributed to its buy rating. The company invested in ThinkMD and scooped John Morikis to its board. It sought approval for icotrokinra for plaque psoriasis and acquired
Halda Therapeutics for $3.05 billion. Scotiabank picked JNJ as a top choice for
curative treatments.
However, JNJ’s novel Alzheimer’s drug failed in a significant trial, dimming hopes. Despite this setback, JNJ's SunRISe-1 Study presents promising results for bladder cancer treatment and the company was able to have several drugs approved.
Johnson Johnson JNJ News Analytics from Mon, 17 Mar 2025 07:00:00 GMT to Sat, 06 Dec 2025 15:24:01 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor 4
